'Provocative' Survival Result in Myelofibrosis Trial

(MedPage Today) -- CHICAGO--A randomized trial testing the addition of selinexor (Xpovio) to ruxolitinib (Jakafi) for myelofibrosis only met one of its two primary endpoints, yet the combination also showed a potential survival benefit.
At...